Being the fastest driver doesn’t mean much when you’re stuck behind a slower car. How about being a fast driver but you burn through tires requiring you to pit early where you lose time to your opponents who don’t have to stop for fresh rubber? For this reason we’re going to be...
包括Kymriah和Yescarta，用于治疗特定类型的白血病和淋巴瘤。这代表了CAR-T疗法在药物治疗领域的重大突破。
但是没有可以保证100%疗效的方法,CAR-T也不例外,比如前面例子提到的CAR-T疗法的靶点是CD19,但是部分患者会出现CD19阴性或低CD19,就可能让CAR-T细胞无法起效或效果很低,医学上被称为「抗原逃逸]。 从这种明星疗法——CAR-T治疗的分析上,我们可以看到,起码在目前阶段,无论宣传多么神奇的疗法,都是有缺点的,也就...
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alternative to CAR-T cells that may overcome som...
Chimeric antigen receptor (CAR)-T cell adoptive immunotherapy is a promising cancer treatment that uses genetically engineered T cells to attack tumors. However, this therapy can have some adverse effects. CAR-T cell-derived exosomes are a potential alte
CAR-T 疗法是一种嵌合抗原受体 T细胞免疫疗法，是一种新型的肿瘤精准靶向治疗，有效杀伤肿瘤细胞，从而...
CAR-T细胞免疫疗法属于过继免疫疗法,基本原理是利用基因工程修饰T淋巴细胞,使其表达嵌合抗原受体,以非MHC (major histocompatibility complex,主要组织相容性复合体)限制性的方式靶向识别肿瘤蛋白质和脂类抗原,不需要经过抗原递呈细胞(antigen-presenting cell,APC),从而杀伤肿瘤细胞,其用来识别靶抗原的结构为单克隆抗体.FDA...
T-cell therapy Adoptive cell therapy Immunotherapy Thoracic cancers Introduction Over the past decade, successful translation of immunotherapeutic agents to the clinic with remarkable response rates in solid tumors, including lung cancer, has reinvigorated interest in further exploiting the discoveries in tum...
The theory that BHB supplementation could improve response to CAR T cell therapy is being tested in aPhase I clinical trialat Penn Medicine's Abramson Cancer Center. "We're talking about an intervention that is relatively cheap and has low toxicity potential," Levy said. "If the clinical tria...
CAR-T细胞疗法先驱 Carl June 教授曾在 Cell 期刊发表评论文章指出，尽管CAR-T细胞治疗红斑狼疮还需要更...